Skip to content
Screener

Financing Cash Flow at other companies

BK
BKBK
$88.3B+318%
Veradermics logo
VeradermicsMANE
$269.11M+3,095%
GPA
General Purpose Acquisition Corp.GPAC
-$4.45K-100%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$250K-86.1%
Schering-Plough logo
Schering-PloughSGP
$157.76M+215%
Lowe's Companies logo
Lowe's CompaniesLOW
-$3.05B-96.1%

Where this comes from

Reported directly by First Tracks Biotherapeutics Inc in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-224190
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Net cash provided by investing activities34,98314,847
CASH FLOWS FROM FINANCING ACTIVITIES:
Net parent investment7,8515,716
Net cash provided by financing activities7,8515,716
Net increase (decrease) in cash and cash equivalents10,273(24,443)
Cash and cash equivalents, beginning of period238,196123,080
Cash and cash equivalents, end of period$248,469$98,637
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Item 1. Combined Financial Statements.

FAQ

What is First Tracks Biotherapeutics Inc's financing cash flow?
First Tracks Biotherapeutics Inc (TRAX) reported financing cash flow of $7.85M in Q1 2026.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about First Tracks Biotherapeutics Inc's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude